{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:13:24Z","timestamp":1765289604079,"version":"3.46.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clinical trials for melanoma patients demonstrated safety of observation in lieu of completion lymph node dissection (CLND) following positive sentinel lymph node (SLN) biopsy. Patients with two or more positive SLNs were infrequently included in the trials, leaving uncertainty about their management. We aimed to (1) assess national trends of CLND use in patients with two or more positive SLNs; (2) examine factors associated with CLND  use; and (3) examine overall survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with stage I\u2013III melanoma who underwent SLN biopsy between 2012 and 2021 were identified from the National Cancer Database. Factors associated with CLND were assessed by hierarchical logistic regression. Overall survival was estimated using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 151,442 patients (median age 61\u00a0years; 41.3% female) who underwent SLN biopsy, 5440 (3.6%) had two or more positive SLNs. CLND in patients with two or more positive SLNs decreased from 73% in 2012 to 14% in 2021, while immunotherapy utilization increased from 38% in 2012 to 76% in 2021. Patients with two or more positive SLNs were more likely to undergo CLND if they had melanoma in the head\/neck region (odds ratio [OR] 2.02, 95% confidence interval [CI] 1.39\u20132.95) or ulcerated lesions (OR 1.42, 95% CI 1.11\u20131.83). There was no difference in 3-year overall survival (70.5% for two or more positive SLNs with observation vs. 70.8% for two or more positive SLNs with CLND; hazard ratio 1.03, 95% CI 0.77\u20131.37) for observation vs. CLND.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Utilization of CLND declined for melanoma patients with two or more positive SLNs following major clinical trials, with no difference in overall survival for observation versus CLND. Evolving treatment recommendations have been rapidly incorporated into practice in the United States.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18466-4","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:38:09Z","timestamp":1762011489000},"page":"397-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes"],"prefix":"10.1245","volume":"33","author":[{"given":"Tyler P.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen N.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Ruedinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hyngstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore F.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Wooden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan J.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl Y.","family":"Bilimoria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"issue":"6","key":"18466_CR1","first-page":"A4441","volume":"59","author":"J Ul-Mulk","year":"2012","unstructured":"Ul-Mulk J, H\u00f6lmich LR. Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity. Dan Med J. 2012;59(6):A4441.","journal-title":"Dan Med J."},{"issue":"2","key":"18466_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/BF02303844","volume":"5","author":"E Joseph","year":"1998","unstructured":"Joseph E, Brobeil A, Glass F, Glass J, Messina J, DeConti R, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol. 1998;5(2):119\u201325.","journal-title":"Ann Surg Oncol."},{"issue":"5\u20136","key":"18466_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10585-018-9898-6","volume":"35","author":"MB Faries","year":"2018","unstructured":"Faries MB, Han D, Reintgen M, Kerivan L, Reintgen D, Carac\u00f2 C. Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials. Clin Exp Metastasis. 2018;35(5\u20136):431\u201342.","journal-title":"Clin Exp Metastasis."},{"issue":"32","key":"18466_CR4","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1200\/JCO.2008.20.9965","volume":"27","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol. 2009;27(32):5445\u201351.","journal-title":"J Clin Oncol."},{"issue":"23","key":"18466_CR5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322.","journal-title":"N Engl J Med."},{"issue":"6","key":"18466_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757\u201367.","journal-title":"Lancet Oncol."},{"issue":"32","key":"18466_CR7","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.18.02306","volume":"37","author":"U Leiter","year":"2019","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al. Final Analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37(32):3000\u20138.","journal-title":"J Clin Oncol."},{"key":"18466_CR8","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Melanoma: CutaneousVersion 2.2024\u2014April 3, 2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf."},{"issue":"11","key":"18466_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361.","journal-title":"Nat Med."},{"key":"18466_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101959","volume":"45","author":"T Olivier","year":"2024","unstructured":"Olivier T, Prasad V. Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial. Transl Oncol. 2024;45:101959.","journal-title":"Transl Oncol."},{"key":"18466_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.004","volume":"182","author":"ACJ van Akkooi","year":"2023","unstructured":"van Akkooi ACJ, Blank C, Eggermont AMM. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. Eur J Cancer. 2023;182:38\u201342.","journal-title":"Eur J Cancer."},{"issue":"5","key":"18466_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522\u201330.","journal-title":"Lancet Oncol."},{"issue":"19","key":"18466_CR13","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med."},{"issue":"19","key":"18466_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u201323.","journal-title":"N Engl J Med."},{"issue":"19","key":"18466_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med."},{"issue":"9","key":"18466_CR16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMc1708918","volume":"377","author":"KY Bilimoria","year":"2017","unstructured":"Bilimoria KY, Russell MC, Hyngstrom J. Melanoma sentinel-node metastasis. N Engl J Med. 2017;377(9):891.","journal-title":"N Engl J Med."},{"issue":"3","key":"18466_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The national cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683\u201390.","journal-title":"Ann Surg Oncol."},{"key":"18466_CR18","unstructured":"American College of Surgeons Commission on Cancer. STandards for Oncology Registry Entry: Revised for 2022."},{"key":"18466_CR19","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Scope of Regional Lymph Node Surgery. 2012. Available at: https:\/\/seer.cancer.gov\/seerstat\/variables\/seer\/regional_ln\/"},{"issue":"13","key":"18466_CR20","doi-asserted-by":"publisher","first-page":"8456","DOI":"10.1245\/s10434-022-12364-9","volume":"29","author":"CE Sharon","year":"2022","unstructured":"Sharon CE, Straker RJ, Li EH, Karakousis GC, Miura JT. National practice patterns in the management of the regional lymph node basin after positive sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol. 2022;29(13):8456\u201364.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"18466_CR21","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1634\/theoncologist.2015-0110","volume":"20","author":"M Ambroggi","year":"2015","unstructured":"Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L. Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist. 2015;20(12):1378\u201385.","journal-title":"Oncologist."},{"key":"18466_CR22","doi-asserted-by":"crossref","unstructured":"Snyder BM, Mounessa JS, Fazzari M, Caravaglio JV, Kretowicz A, Braunberger T, et al. Greater distance to an academic medical center is associated with poorer melanoma prognostic factors: The University of Colorado Experience. Dermatol Online J. 2017;23(11).","DOI":"10.5070\/D32311037246"},{"issue":"4","key":"18466_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cncr.23229","volume":"112","author":"T Onega","year":"2008","unstructured":"Onega T, Duell EJ, Shi X, Wang D, Demidenko E, Goodman D. Geographic access to cancer care in the US. Cancer. 2008;112(4):909\u201318.","journal-title":"Cancer."},{"issue":"11","key":"18466_CR24","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1245\/s10434-016-5242-z","volume":"23","author":"N Wasif","year":"2016","unstructured":"Wasif N, Chang YH, Pockaj BA, Gray RJ, Mathur A, Etzioni D. Association of distance traveled for surgery with short- and long-term cancer outcomes. Ann Surg Oncol. 2016;23(11):3444\u201352.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"18466_CR25","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1245\/s10434-008-9885-2","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Balch CM, Bentrem DJ, Talamonti MS, Ko CY, Lange JR, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15(6):1566\u201376.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"18466_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jso.25160","volume":"118","author":"DB Hewitt","year":"2018","unstructured":"Hewitt DB, Merkow RP, Delancey JO, Wayne JD, Hyngstrom JR, Russell MC, et al. National practice patterns of completion lymph node dissection for sentinel node-positive melanoma. J Surg Oncol. 2018;118(3):493\u2013500.","journal-title":"J Surg Oncol."},{"issue":"2","key":"18466_CR27","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1245\/s10434-022-12745-0","volume":"30","author":"JT Castle","year":"2023","unstructured":"Castle JT, Adatorwovor R, Levy BE, Marcinkowski EF, Merritt A, Stapleton JL, et al. Completion lymph node dissection for melanoma before and after the multicenter selective lymphadenectomy trial-II in the United States. Ann Surg Oncol. 2023;30(2):1184\u201393.","journal-title":"Ann Surg Oncol."},{"key":"18466_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.17161\/kjm.vol1414674","volume":"14","author":"S Breit","year":"2021","unstructured":"Breit S, Foley E, Ablah E, Okut H, Mammen J. Recent evolution in the management of lymph node metastases in melanoma. Kans J Med. 2021;14:64\u201372.","journal-title":"Kans J Med."},{"issue":"4","key":"18466_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1001\/jama.297.4.403","volume":"297","author":"JM Westfall","year":"2007","unstructured":"Westfall JM, Mold J, Fagnan L. Practice-based research\u2014\"blue highways\" on the NIH roadmap. JAMA. 2007;297(4):403\u20136.","journal-title":"JAMA."},{"issue":"6","key":"18466_CR30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/jso.26119","volume":"122","author":"K Huang","year":"2020","unstructured":"Huang K, Misra S, Lemini R, Chen Y, Speicher LL, Dawson NL, et al. Completion lymph node dissection in patients with sentinel lymph node positive cutaneous head and neck melanoma. J Surg Oncol. 2020;122(6):1057\u201365.","journal-title":"J Surg Oncol."},{"issue":"5","key":"18466_CR31","doi-asserted-by":"publisher","first-page":"e1106","DOI":"10.1097\/SLA.0000000000005370","volume":"277","author":"KK Broman","year":"2023","unstructured":"Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, et al. International center-level variation in utilization of completion lymph node dissection and adjuvant systemic therapy for sentinel lymph node-positive melanoma at major referral centers. Ann Surg. 2023;277(5):e1106\u201315.","journal-title":"Ann Surg."},{"issue":"11","key":"18466_CR32","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1200\/JCO.2008.18.7567","volume":"27","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Balch CM, Wayne JD, Chang DC, Palis BE, Dy SM, et al. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol. 2009;27(11):1857\u201363.","journal-title":"J Clin Oncol."},{"issue":"4","key":"18466_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.35772\/ghm.2020.01022","volume":"2","author":"A Ari\u00e9","year":"2020","unstructured":"Ari\u00e9 A, Yamamoto T. Lymphedema secondary to melanoma treatments: diagnosis, evaluation, and treatments. Glob Health Med. 2020;2(4):227\u201334.","journal-title":"Glob Health Med."},{"issue":"4","key":"18466_CR34","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00403-022-02433-0","volume":"315","author":"KM Mulligan","year":"2023","unstructured":"Mulligan KM, Zheng DX, Xu JR, Cullison CR, Cwalina TB, Beveridge MG, et al. Geographic disparities in access to immunotherapy clinical trials for metastatic melanoma. Arch Dermatol Res. 2023;315(4):1033\u20136.","journal-title":"Arch Dermatol Res."},{"issue":"10","key":"18466_CR35","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/1346-8138.14577","volume":"45","author":"OD Persa","year":"2018","unstructured":"Persa OD, Knuever J, Mauch C, Schlaak M. Complete lymph node dissection or observation in melanoma patients with multiple positive sentinel lymph nodes: a single-center retrospective analysis. J Dermatol. 2018;45(10):1191\u20134.","journal-title":"J Dermatol."},{"issue":"4","key":"18466_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jamcollsurg.2020.11.014","volume":"232","author":"KK Broman","year":"2021","unstructured":"Broman KK, Hughes TM, Dossett LA, Sun J, Carr MJ, Kirichenko DA, et al. Surveillance of sentinel node-positive melanoma patients with reasons for exclusion from MSLT-II: multi-institutional propensity score matched analysis. J Am Coll Surg. 2021;232(4):424\u201331.","journal-title":"J Am Coll Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18466-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:09:04Z","timestamp":1765289344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18466-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18466"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18466-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Theodore F. Logan has received research funding for clinical trials, paid to his institution, from Abbott, Abraxis, Acceleron, Amgen, Argos, AstraZeneca, Aveo, Biovex, Bristol-Myers Squibb, Eisai, Lilly, GlaxoSmirhKline, Roche, Immatics, Merck, Novartis, Pfizer, Synta, Threshold Pharmaceuticals, Millenium, Tracon, Cerulean, EMD Sorono, Prometheus, Macrogenics, Peleton, Iovance, MedImmune, Dynavax, NiKang, and Clinigen. Tyler P. Robinson, Kristen N. Kaiser, Brian Ruedinger, John Hyngstrom, William A. Wooden, Ryan J. Ellis, and Karl Y. Bilimoria have no conflicts of interests to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}